Introduction
NSCLCs, Non-small cell lung cancers, tumor
TUMOR, NON-SMALL CELL LUNG CANCER
Non-small cell lung cancers (NSCLCs) with acquired epidermal growth factor receptor (EGFR TKIs represent an advance in the first-line treatment of In this challenging environment, options for the subsequent treatment of Given the limitations of the current treatments, there is a need for alternative approaches to treat progressive DS-1205c is a novel, specific, small-molecule AXL inhibitor that has been developed as an oral antitumor agent for use in combination with EGFR TKIs. In tumor xenograft models, the addition of DS-1205c restored sensitivity to EGFR TKIs in cells with the 